SLRX stock Salarius Pharmaceuticals NASDAQ 18 Mar 2026: Earnings 19 Mar

SLRX stock jumped 29.23% intraday to $0.84 as traders position ahead of Salarius Pharmaceuticals’ earnings call on 19 Mar 2026. This intraday move follows heavy trading volume of 5,962,438 shares versus a 50-day average of 3,681,706. We review catalysts, valuation, technicals, and the near-term earnings risk for investors watching this NASDAQ-listed US biotech.

SLRX stock intraday move and earnings timing

The most immediate fact is price action: SLRX stock traded between $0.69 and $0.90 today with an open at $0.71. The share count stands at 5,862,178 outstanding. The company reports results on 19 Mar 2026 after the market close, a likely catalyst for continued volatility.

Volume is elevated at 5,962,438 shares, a relative volume of 1.62, which signals stronger than normal intraday interest ahead of the earnings announcement.

SLRX stock valuation and key financials

Salarius shows a tiny market capitalization of $4,924,230.00 and an enterprise value near $114,550.00. Trailing EPS is -24.24 and the reported PE is -0.03, reflecting deep losses and clinical-stage status.

Balance-sheet metrics include cash per share $9.99, book value per share $8.82, and a current ratio of 5.49, which indicate cash strength relative to liabilities despite operating losses.

Meyka AI grade: SLRX stock score and context

Meyka AI rates SLRX with a score out of 100: 67.22 — Grade B, suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus.

This score is informational and not a guarantee. Investors should consider risk around clinical outcomes and potential delisting notices when weighing the grade.

SLRX stock clinical pipeline and near-term catalysts

Salarius focuses on epigenetic oncology drugs, led by Seclidemstat (SP-2577) in Phase I/II trials and SP-3164 preclinical programs. A positive trial update or licensing deal could drive price moves.

Note: some market outlets flagged possible delisting concerns for Salarius. See recent coverage on MarketBeat and regional listings on Investing.com.

SLRX stock technicals and trading setup

Short-term technicals show RSI 51.27, ADX 48.61, and ATR 0.08, consistent with a strong intraday trend. The 50-day price average is $1.12 and the 200-day average is $6.94, indicating long-term downtrend pressure.

Liquidity is thin relative to major names, but today’s volume of 5,962,438 exceeded the average daily volume of 3,681,706, increasing intraday liquidity and widening bid-ask risk.

SLRX stock risks and opportunities

Upside is binary: a favorable clinical readout or licensing deal could lift valuation rapidly. Downside risks include trial failure, thin market cap, and delisting notices.

Financially, Salarius holds $9.99 cash per share versus enterprise value $114,550.00, a structural asset buffer if management converts assets or raises capital. Investors should weigh cash runway against development costs and dilution risk.

Final Thoughts

SLRX stock is trading as a high-volatility clinical-stage biotech ahead of the 19 Mar 2026 earnings event. The stock sits at $0.84 with elevated volume and clear binary catalysts tied to clinical development and corporate updates. Fundamental ratios show deep losses, with EPS -24.24 and a negative PE. Meyka AI’s forecast model projects a near-term target of $2.36 per share. That implies an upside of 180.95% versus the current $0.84 price, but forecasts are model-based projections and not guarantees. Given the company’s small market cap of $4,924,230.00, potential delisting flags, and thin long-term trading averages, the risk-reward profile is speculative. Investors who trade SLRX stock should size positions for significant volatility, monitor the earnings release closely, and review the company’s clinical updates and any listing notices. For a centralized data view visit the Meyka SLRX profile for live updates and deeper metrics: https://meyka.ai/stocks/SLRX

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.